Business Context and Reporting Period
Incannex Healthcare Inc. is a Delaware clinical-stage biopharmaceutical company developing oral fixed-dose combinations and psychedelic-assisted therapies for serious chronic conditions. The fiscal year ended June 30, 2026, and the filing was signed September 25, 2026. The company has no approved commercial products and has not generated product-sale revenue.
- IHL-42X: Lead candidate for obstructive sleep apnea, combining dronabinol and acetazolamide. The Phase 2 portion of the RePOSA study was completed in July 2025 with reported improvements in apnea-hypopnea index, oxygenation and patient-reported outcomes. FDA Fast Track designation was granted in December 2025.
- DReAMzz: Phase 2 dose-confirmation crossover study evaluating nine dose combinations in approximately 120 subjects at 14 U.S. sites. It commenced in May 2026, began screening in July 2026, remains ongoing and is estimated to complete in mid-2027. Results are intended to inform a planned Phase 3 program.
- PSX-001: Oral synthetic psilocybin administered with psychological therapy for generalized anxiety disorder. The completed PsiGAD1 Phase 2 trial reported statistically meaningful improvements in anxiety and secondary measures, with no serious adverse events reported among 73 participants. The company is revising its next-stage development plan.
- IHL-675A: CBD and hydroxychloroquine combination for inflammatory conditions, initially rheumatoid arthritis. The Australian Phase 2 trial was terminated after recruitment difficulties; insufficient data were collected to draw safety or efficacy conclusions.
Financial Results and Key Metrics
| U.S. dollars in thousands, except per-share data | FY2026 | FY2025 | Change |
|---|---|---|---|
| Revenue from customers | — | 86 | (100%) |
| Research and development expense | 5,210 | 10,747 | (52%) |
| General and administrative expense | 17,817 | 13,128 | 36% |
| Total operating expenses | 23,027 | 23,875 | (4%) |
| Loss from operations | (23,027) | (23,789) | 3% improvement |
| R&D tax incentive | 4,658 | 1,756 | 165% increase |
| Net loss | (19,302) | (46,885) | 59% improvement |
| Comprehensive loss | (19,754) | (46,677) | 58% improvement |
| Basic and diluted loss per share | (1.66) | (40.82) | Not directly comparable due to share changes and reverse split |
| Net cash used in operating activities | (12,867) | (12,513) | 3% higher outflow |
| Net cash provided by financing activities | 65,903 | 21,396 | 44,507 increase |
- Cash and cash equivalents were $67.7 million at June 30, 2026, compared with $15.0 million at June 30, 2025. Unrestricted cash was reported at $68.4 million as of September 24, 2026.
- Current assets exceeded current liabilities by $71.3 million at June 30, 2026, compared with $13.0 million in the prior year.
- Total assets were $73.0 million, total liabilities were $5.6 million and stockholders’ equity was $67.4 million at June 30, 2026.
- There was no outstanding conventional debt reported at year-end. Liabilities included $4.1 million of warrant liabilities and $96,000 of operating lease liabilities.
- Operating cash use remained substantial. Management stated that available resources are expected to fund planned operations and capital requirements for at least twelve months from the financial-statement issuance date, but additional capital will be required beyond that period.
- There were no material profitability or operating margins to report because the company remains loss-making and generated no customer revenue in FY2026.
Material Changes Versus the Prior Comparable Period
- Revenue declined to zero from $86,000 because the company generated no clinic-patient rehabilitation revenue in FY2026 and has not generated product revenue.
- R&D expense fell by $5.5 million, primarily reflecting completion of the RePOSA Phase 2 portion and the timing of the DReAMzz launch. Management expects R&D spending to increase as clinical programs advance.
- G&A expense rose by $4.7 million, driven mainly by stock-based compensation, which increased from $2.6 million to $7.6 million, and modestly higher employee costs.
- Net loss improved by $27.6 million, largely because FY2025 included significant financing-related losses, including a $21.9 million warrant fair-value loss, a $1.5 million debt extinguishment loss and a $1.1 million ELOC commitment fee.
- FY2026 financing inflows increased primarily due to $78.7 million of share issuance proceeds. These inflows were partly offset by $9.4 million of share repurchases, $3.1 million of share issuance costs and $284,000 of warrant issuance costs.
- The company issued 8.27 million shares during FY2026 and repurchased 2.21 million shares. Shares outstanding were 12.54 million at June 30, 2026, compared with 6.48 million at June 30, 2025, after giving effect to the 1-for-30 reverse stock split completed in February 2026.
- The company repurchased 1.81 million shares for $9.4 million during the quarter ended June 30, 2026. The $20 million repurchase program expired August 30, 2026.
Guidance, Outlook, Risks and Unusual Items
- Management’s principal near-term milestone is completion of DReAMzz in mid-2027, followed by dose analysis and design of a planned Phase 3 IHL-42X trial.
- The company is evaluating the next clinical development plan for PSX-001, including potential changes to the Phase 2 design. No specific timing or financial guidance was provided.
- IHL-675A is deprioritized while resources focus on IHL-42X and PSX-001. Its terminated Phase 2 study did not provide sufficient data to assess safety or efficacy.
- The company relies heavily on equity financing, Australian R&D tax incentives and potential future collaborations. It expects substantial additional funding will be needed, creating dilution and execution risk.
- The filing states that the company no longer has substantial doubt regarding going concern for at least twelve months, but it remains loss-making, cash-flow negative and dependent on future capital to continue development beyond that period.
- Management identified a material weakness in internal control over financial reporting caused primarily by limited accounting personnel and inadequate segregation of duties. Disclosure controls were therefore deemed ineffective as of June 30, 2026. Remediation is in progress, but no completion date was provided.
- Clinical development remains subject to uncertain efficacy, safety, enrollment, manufacturing, regulatory and timing outcomes. The decision to add the DReAMzz study delayed the originally contemplated Phase 3 path for IHL-42X.
- The lead programs involve controlled substances, including synthetic cannabinoids and psilocybin, subject to FDA, DEA and international controls. Scheduling, permitting, quotas, importation and manufacturing requirements could delay development or commercialization.
- The company relies on third-party contract research organizations and manufacturers, including Procaps and Ardena. Supply interruptions, quality failures or regulatory noncompliance could delay trials.
- In June 2026, the USPTO granted a key IHL-42X patent. As of September 2026, the company reported two granted IHL-42X patents and 18 pending applications; patent protection for PSX-001 remains under evaluation.
- On August 11, 2026, the company received a final A$5.1 million Australian R&D tax incentive refund related to the fiscal 2025 claim. Total cash refunds related to that claim exceeded A$11.2 million.
- The company regained Nasdaq minimum bid-price compliance after completing the reverse stock split, but warns that future noncompliance could result in delisting.
- No material litigation was reported, and the company reported no material cybersecurity incidents during the fiscal year.
Most Important Facts for Investors to Verify
- Verify the audited balance sheet, cash balance, warrant liabilities and the composition and terms of the FY2026 equity financings.
- Assess expected cash burn and whether the stated twelve-month liquidity runway adequately covers DReAMzz, planned Phase 3 preparation and PSX-001 planning.
- Review DReAMzz enrollment, dose-selection results and the resulting Phase 3 design and regulatory feedback.
- Evaluate whether PsiGAD1 results can be replicated in a larger, well-controlled study and confirm the timing and design of the next PSX-001 trial.
- Monitor remediation of the material weakness and any subsequent auditor or management assessment of internal controls.
- Confirm the status, scope and enforceability of IHL-42X patents and the company’s developing IP strategy for PSX-001.
- Track DEA and other regulatory developments affecting cannabis-derived substances and psilocybin, including scheduling and trial-manufacturing permissions.
- Consider dilution from additional equity offerings, outstanding warrants and other equity-linked instruments, as well as Nasdaq listing compliance.